Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 1;34(11):1700-1718.
doi: 10.1016/j.cmet.2022.09.017. Epub 2022 Oct 7.

Gut-liver axis: Pathophysiological concepts and clinical implications

Affiliations
Free article
Review

Gut-liver axis: Pathophysiological concepts and clinical implications

Herbert Tilg et al. Cell Metab. .
Free article

Abstract

Bidirectional crosstalk along the gut-liver axis controls gastrointestinal health and disease and exploits environmental and host mediators. Nutrients, microbial antigens, metabolites, and bile acids regulate metabolism and immune responses in the gut and liver, which reciprocally shape microbial community structure and function. Perturbation of such host-microbe interactions is observed in a variety of experimental liver diseases and is facilitated by an impaired intestinal barrier, which is fueling hepatic inflammation and disease progression. Clinical evidence describes perturbation of the gut-liver crosstalk in non-alcoholic fatty liver disease, alcoholic liver disease, and primary sclerosing cholangitis. In liver cirrhosis, a common sequela of these diseases, the intestinal microbiota and microbial pathogen-associated molecular patterns constitute liver inflammation and clinical complications, such as hepatic encephalopathy. Understanding the intricate metabolic interplay between the gut and liver in health and disease opens an avenue for targeted therapies in the future, which is probed in controlled clinical trials.

Keywords: gut microbiome; gut-liver axis; leaky gut; liver disease.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.T. has served as speaker for Falk Foundation, Gilead, Intercept, and MSD; he has advised for Albireo, BiomX, Boehringer Ingelheim, Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Jannsen, MSD, Novartis, Phenex, Regulus, and Shire. He further received travel grants from Abbvie, Falk, Gilead, and Intercept and research grants from Albireo, Almylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and Ultragenyx.

Publication types

MeSH terms

LinkOut - more resources